2025 Asia-Pacific Antibodies Contract Manufacturing Revenue Opportunities Report
Description
The 2025 Asia-Pacific Antibodies Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest antibody contract manufacturing organizations (CMOs) actively involved in the Asia-Pacific region are Samsung Biologics, AGC Biologics, WuXi Biologics, and Lonza. Samsung Biologics leads with a monoclonal antibody manufacturing capacity exceeding 360,000 liters and is a key player based in South Korea, providing extensive CDMO services with a strong regional focus. AGC Biologics, headquartered in the US but with significant Asia-Pacific operations, offers comprehensive development and manufacturing services and has recently expanded its mammalian bioreactor capacity in Copenhagen and invested in new Japanese facilities. WuXi Biologics, a Chinese giant in biologics, delivers end-to-end antibody manufacturing from early development to commercial production, with over 30,000 liters capacity and global facilities including in Singapore and China. Lonza, a Swiss multinational, is a major global CMO with strong presence in Asia-Pacific, offering integrated services supporting monoclonal antibody production among other biologics.
These companies contribute significantly to the growing Asia-Pacific antibody contract manufacturing market, which generated revenue of approximately USD 6.8 billion in 2023 and is expected to grow rapidly (14.2% CAGR through 2030). Their strengths include large-scale mammalian bioreactor capacity, advanced technology platforms, and strategic facility expansions in manufacturing hubs such as China, South Korea, Japan, and Singapore. Together, they enable regional and global biopharmaceutical companies to accelerate antibody therapeutic development and commercialization within this fastest-growing market segment.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest antibody contract manufacturing organizations (CMOs) actively involved in the Asia-Pacific region are Samsung Biologics, AGC Biologics, WuXi Biologics, and Lonza. Samsung Biologics leads with a monoclonal antibody manufacturing capacity exceeding 360,000 liters and is a key player based in South Korea, providing extensive CDMO services with a strong regional focus. AGC Biologics, headquartered in the US but with significant Asia-Pacific operations, offers comprehensive development and manufacturing services and has recently expanded its mammalian bioreactor capacity in Copenhagen and invested in new Japanese facilities. WuXi Biologics, a Chinese giant in biologics, delivers end-to-end antibody manufacturing from early development to commercial production, with over 30,000 liters capacity and global facilities including in Singapore and China. Lonza, a Swiss multinational, is a major global CMO with strong presence in Asia-Pacific, offering integrated services supporting monoclonal antibody production among other biologics.
These companies contribute significantly to the growing Asia-Pacific antibody contract manufacturing market, which generated revenue of approximately USD 6.8 billion in 2023 and is expected to grow rapidly (14.2% CAGR through 2030). Their strengths include large-scale mammalian bioreactor capacity, advanced technology platforms, and strategic facility expansions in manufacturing hubs such as China, South Korea, Japan, and Singapore. Together, they enable regional and global biopharmaceutical companies to accelerate antibody therapeutic development and commercialization within this fastest-growing market segment.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
